Published 1 month ago • loading... • Updated 1 month ago

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

Summary by Macau Business

MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or ‘ANVISA’) has approved Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) the Company’s lead prostate cancer imaging agent. Illuccix® is the first and only PSMA-PET[1…

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

7 Articles

All

Left

Center

Right

Medical Device Network

Telix's prostate cancer imaging agent approved in Brazil

Brazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer imaging agent.The post Telix’s prostate cancer imaging agent approved in Brazil appeared first on Medical Device Network.

1 month ago

Read Full Article

1fakt.com

Experts reveal the SIX foods you need to help beat prostate cancer

Proper news from Britain - News from Britain you won’t find anywhere else. Not the tosh the big media force-feed you every day!

1 month ago

Read Full Article

stocktitan.net

Major Breakthrough: First PSMA-PET Imaging Agent Approved in Brazil's $330M Market

Telix's Illuccix secures landmark Brazilian approval for prostate cancer imaging, partnering with R2PHARMA to tap into $330M radiopharmaceutical market opportunity.

1 month ago

Read Full Article

Telix

+3 Reposted by 3 other sources

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

Melbourne (Australia) | 18 March 2025 Telix today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or ‘ANVISA’) has approved Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) the Company’s lead prostate cancer imaging agent. Illuccix® is the first and only PSMA-PET[1] prostate cancer imaging agent to receive full regulatory approval in Brazil. Illuccix®, after radiolabe…

1 month ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year